Skip to main content
. 2022 Nov 15;66:101638. doi: 10.1016/j.molmet.2022.101638

Figure 6.

Figure 6

GIPR antagonism via Peptide 7 enhances GLP-1 mediated weight loss. (A) Percent change in body weight and (B) cumulative food intake for DIO mice treated with either semaglutide (2 nmol/kg QD), 7 (500 or 1500 nmol/kg QD), or semaglutide + 7 (2 nmol/kg QD + either 500 or 1500 nmol/kg QD) for 27 d. The blood glucose (A) and glucose iAUC (B) were assessed in an IPGTT on day 26. On day 27 animals were fasted for 6 h and plasma was collected for assessment of (C) insulin, (D) resistin, and (E) CTX. Data represent mean ± SEM, n = 8 per group. ∗ represents p < 0.05 compared to either vehicle or indicated group; ˆ indicates p < 0.05 between semaglutide vs. semaglutide +7 (1500 nmol/kg.